Schmidt, Lejla Sjanic
Petersen, Jeff Zarp
Vinberg, Maj
Hageman, Ida
Olsen, Niels Vidiendal
Kessing, Lars Vedel
Jørgensen, Martin Balslev
Miskowiak, Kamilla Woznica
Funding for this research was provided by:
Mental Health Services - Capital Region of Denmark
The Augustinus Foundation (16-2420)
Article History
Received: 15 November 2017
Accepted: 3 April 2018
First Online: 19 April 2018
Ethics approval and consent to participate
: The study has been approved by the Danish Medicines Agency (EudraCT number 2016-002326- 36), the Ethics Committee in the Capital Region of Denmark (protocol number H-16038506), and the Danish Data Protection Agency Capital Region of Denmark (protocol number RHP-2017-023), and it has been registered at ClinicalTrials.gov (NCT03339596) ExternalRef removed on the 10th of November 2017 (retrospectively registered). Any important protocol modifications will be reported to the Danish Medicines Agency, the Ethics Committee in the Capital Region of Denmark, and the Danish Data Protection Agency. Written informed consent has been and will be obtained from all participants.
: KWM has received consultancy fees from Lundbeck and Allergan. Within the past 3 years, MBJ has received speaker fees for Lundbeck and consultant fees for Shire. MV discloses consultancy fees from Lundbeck and AstraZeneca within the last 3 years. LVK reports having been a consultant for Lundbeck, AstraZeneca, and Sunovion within the last 3 years. LSS, JZP, IH, and NVO declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.